Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

jhcimmu

To: luckydog88 who wrote (63106)	5/8/2025 9:53:55 AM
From: luckydog88	1 Recommendation of 63285

couple of more analysts on SPRT today/yesterday afternoon: Wells Fargo analyst Yanan Zhu maintains Sarepta Therapeutics(SRPT) with a Overweight and lowers the price target from $115 to $100. UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics(SRPT) with a Sector Perform and lowers the price target from $87 to $58.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next